Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication Ferric citrate tablets are a phosphate binder indicated for the control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis. ( 1 ) Ferric citrate tablets are an iron replacement product indicated for the treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis. FDA label
Also known as ferric citrate, Auryxia, PhosLo, Renvela, Zerenex
KRX-0502 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| KRX-0502 | EXPERIMENTAL | KRX-0502 (ferric citrate) |
| Name | Type | Description |
|---|---|---|
| KRX-0502 | DRUG | 1g tablets of KRX-0502 |
Inclusion Criteria: * Males and non-lactating females with negative serum pregnancy test (for females of child-bearing potential) at Screening * Age ≥ 18 years * Serum ferritin ≤ 300 ng/mL and TSAT ≤ 25% at Screening * Hemoglobin ≥9.0 g/dL and ≤11.5 g/dL at Screening * eGFR \<60 mL/min at Screening...
KRX-0502 is an investigational small molecule developed by Akebia Therapeutics, Inc. for anemia of chronic kidney disease. It was studied as ferric citrate administered without food to treat iron-deficiency anemia in adults with chronic kidney disease. It is a Phase 2 candidate and is not approved for marketing.
KRX-0502 was studied for the treatment of iron-deficiency anemia in adults with anemia of chronic kidney disease. The pilot study enrolled adults aged 18 years and older and evaluated ferric citrate given without food. The program is in Phase 2 development and no approved use has been established.
KRX-0502 is developed by Akebia Therapeutics, Inc., which trades on the Nasdaq under the ticker AKBA. Akebia is the sponsor of the clinical program evaluating the candidate in anemia of chronic kidney disease.
KRX-0502 is in Phase 2 development. Its single recorded trial, NCT02128074, is a completed Phase 2 pilot study. The drug is investigational and has not been approved by the FDA for any indication.
KRX-0502 has been evaluated in one clinical trial, NCT02128074, titled a pilot study of KRX-0502 (ferric citrate) administered without food in treating iron-deficiency anemia. That Phase 2 trial is completed, enrolled 32 participants, and was conducted in Israel. It was an uncontrolled study without randomization or blinding.
KRX-0502 is ferric citrate. The Phase 2 pilot trial NCT02128074 describes the study drug as KRX-0502 (ferric citrate) administered without food in treating iron-deficiency anemia in patients with anemia of chronic kidney disease.